Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of pemetrexed + carboplatin versus gemcitabine + vinorelbine in pretreated advanced breast cancer
2006-000441-19Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Pemetrexed + carboplatin with Gemcitabine + vinorelbine (2 arms). Primary endpoint: Clinical response rate. Started Feb 2006; status: completed.
02
Drugs
pemetrexedcarboplatingemcitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000441-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000441-19.